The Diagnostic Value of CSF Amyloid-beta43 in Differentiation of Dementia Syndromes

There is no fulltext present in this item.

Title:	The Diagnostic Value of CSF Amyloid-beta43 in Differentiation of Dementia Syndromes
Author(s):	Bruggink, K.A.; Kuiperij, H.B. ; Claassen, J.A.H.R. ; Verbeek, M.M.
Publication year:	2013
Source:	Current Alzheimer Research, vol. 10, iss. 10, (2013), pp. 1034-1040
ISSN:	1567-2050
DOI:	https://doi.org/10.2174/15672050113106660168
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/126092
Display more details
Subject:	DCN MP - Plasticity and memory DCN NN - Brain networks and neuronal communication DCN PAC - Perception action and control NCEBP 11: Alzheimer Centre
Organization:	Neurology Laboratory of Genetic, Endocrine and Metabolic Diseases Geriatrics
Journal title:	Current Alzheimer Research
Volume:	vol. 10
Issue:	iss. 10
Page start:	p. 1034
Page end:	p. 1040
Abstract:	Amyloid-beta (Abeta) is known as the most prominent core protein in Alzheimer's Disease (AD) senile plaques. Although research has focused mainly on Abeta40 and Abeta42 as potential cerebrospinal fluid (CSF) biomarkers, a range of Abeta peptides with variable lengths has been demonstrated in the brains and CSF of AD patients. Recently, it has been found that the Abeta43 peptide may be more abundant than previously assumed, could therefore play an important role in AD pathophysiology, and hence also function as putative biomarker. In this study the value of CSF Abeta43 in AD diagnosis was investigated. Abeta43 levels in CSF were highly correlated with Abeta42 levels. Furthermore, in differentiation of AD from nondemented controls and from patients with Lewy body dementia and frontotemporal dementia, Abeta43 had an equal diagnostic value as Abeta42, both as a single biomarker and in combination with total and phosphorylated tau. In conclusion, quantification of Abeta43 in CSF does not add novel diagnostic information to the differential diagnosis of AD compared to existing biomarkers.